Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Richter’s transformation is a rare very aggressive complication of CLL. Learn the role of stem cell transplants in treating Richter’s transformation.
Richter’s transformation is a rare complication of CLL and changes in how clinical trials are conducted might help patients access novel therapies.
Epcoritamab, a bispecific antibody, led to a 50% overall and 35% complete response rate in all Richter’s transformation patients.
For patients with Richter’s transformation, the combination of ibrutinib, venetoclax, and obinutuzumab may be most useful as a bridge to other therapies.
The combination therapy of tislelizumab plus zanubrutinib is effective and well-tolerated for patients with Richter’s transformation.
While the incidence of Richter’s transformation has not changed dramatically with the introduction of targeted therapies, those who received CLL / SLL treatment in the targeted therapy era appear to have a lower risk of Richter’s transformation.
Pirtobrutinib is a useful treatment option to temporarily manage Richter’s transformation, but long-term treatments are still needed.
Chimeric antigen receptor T-cell (CAR-T) therapy can provide durable remissions in a subset of patients with Richter’s transformation.
This was a very complex basic science presentation from iwCLL 2023 by Erin Parry, MD. Ph.D. of Dana Farber Cancer Institute in Boston, MA on the evolution of CLL (chronic lymphocytic leukemia) to Richter’s transformation (RT),
One click to our most popular content.
